Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Primary Sclerosing Cholangitis market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Primary Sclerosing Cholangitismarket, defines the market attractiveness level of Primary Sclerosing Cholangitis market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Primary Sclerosing Cholangitis industry, describes the types of Primary Sclerosing Cholangitis market, the applications of major players and the market size, and deeply analyzes the current situation of the global Primary Sclerosing Cholangitis market and the development prospects and opportunities of Primary Sclerosing Cholangitis industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Primary Sclerosing Cholangitis market in Chapter 13.
By Player:
Shire Plc
NGM Biopharmaceuticals Inc
Conatus Pharmaceuticals Inc
Dr Falk Pharma GmbH
Shenzhen HighTide Biopharmaceuticals Ltd
Allergan Plc
Acorda Therapeutics Inc
Sirnaomics Inc
Durect Corporation
Intercept Pharmaceuticals Inc
Gilead Sciences Inc
By Type:
Type I
Type II
By End-User:
Hospital
Clinics
Other
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Primary Sclerosing Cholangitis Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Primary Sclerosing Cholangitis Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Primary Sclerosing Cholangitis Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Primary Sclerosing Cholangitis Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Primary Sclerosing Cholangitis Market Analysis and Outlook to 2022
-
7.1 Global Primary Sclerosing Cholangitis Consumption (2017-2022)
-
7.2 United States Primary Sclerosing Cholangitis Consumption (2017-2022)
-
7.3 Europe Primary Sclerosing Cholangitis Consumption (2017-2022)
-
7.4 China Primary Sclerosing Cholangitis Consumption (2017-2022)
-
7.5 Japan Primary Sclerosing Cholangitis Consumption (2017-2022)
-
7.6 India Primary Sclerosing Cholangitis Consumption (2017-2022)
-
7.7 South Korea Primary Sclerosing Cholangitis Consumption (2017-2022)
8 Region and Country-wise Primary Sclerosing Cholangitis Market Analysis and Outlook to 2028
-
8.1 Global Primary Sclerosing Cholangitis Consumption Forecast (2022-2028)
-
8.2 United States Primary Sclerosing Cholangitis Consumption Forecast (2022-2028)
-
8.3 Europe Primary Sclerosing Cholangitis Consumption Forecast (2022-2028)
-
8.4 China Primary Sclerosing Cholangitis Consumption Forecast (2022-2028)
-
8.5 Japan Primary Sclerosing Cholangitis Consumption Forecast (2022-2028)
-
8.6 India Primary Sclerosing Cholangitis Consumption Forecast (2022-2028)
-
8.7 South Korea Primary Sclerosing Cholangitis Consumption Forecast (2022-2028)
9 Global Primary Sclerosing Cholangitis Market Outlook by Types and Applications to 2022
-
9.1 Global Primary Sclerosing Cholangitis Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Type I Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Type II Consumption and Growth Rate (2017-2022)
-
9.2 Global Primary Sclerosing Cholangitis Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Other Consumption and Growth Rate (2017-2022)
10 Global Primary Sclerosing Cholangitis Market Outlook by Types and Applications to 2028
-
10.1 Global Primary Sclerosing Cholangitis Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Type I Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Type II Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Primary Sclerosing Cholangitis Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)
11 Global Primary Sclerosing Cholangitis Import and Export Analysis (Top 5 Countries)
-
11.1 Global Primary Sclerosing Cholangitis Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Primary Sclerosing Cholangitis Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Primary Sclerosing Cholangitis Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Primary Sclerosing Cholangitis Market Competitive Analysis
-
14.1 Shire Plc
-
14.1.1 Shire Plc Company Details
-
14.1.2 Shire Plc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Shire Plc Primary Sclerosing Cholangitis Product and Service
-
14.2 NGM Biopharmaceuticals Inc
-
14.2.1 NGM Biopharmaceuticals Inc Company Details
-
14.2.2 NGM Biopharmaceuticals Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 NGM Biopharmaceuticals Inc Primary Sclerosing Cholangitis Product and Service
-
14.3 Conatus Pharmaceuticals Inc
-
14.3.1 Conatus Pharmaceuticals Inc Company Details
-
14.3.2 Conatus Pharmaceuticals Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Conatus Pharmaceuticals Inc Primary Sclerosing Cholangitis Product and Service
-
14.4 Dr Falk Pharma GmbH
-
14.4.1 Dr Falk Pharma GmbH Company Details
-
14.4.2 Dr Falk Pharma GmbH Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Dr Falk Pharma GmbH Primary Sclerosing Cholangitis Product and Service
-
14.5 Shenzhen HighTide Biopharmaceuticals Ltd
-
14.5.1 Shenzhen HighTide Biopharmaceuticals Ltd Company Details
-
14.5.2 Shenzhen HighTide Biopharmaceuticals Ltd Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Shenzhen HighTide Biopharmaceuticals Ltd Primary Sclerosing Cholangitis Product and Service
-
14.6 Allergan Plc
-
14.6.1 Allergan Plc Company Details
-
14.6.2 Allergan Plc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Allergan Plc Primary Sclerosing Cholangitis Product and Service
-
14.7 Acorda Therapeutics Inc
-
14.7.1 Acorda Therapeutics Inc Company Details
-
14.7.2 Acorda Therapeutics Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Acorda Therapeutics Inc Primary Sclerosing Cholangitis Product and Service
-
14.8 Sirnaomics Inc
-
14.8.1 Sirnaomics Inc Company Details
-
14.8.2 Sirnaomics Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Sirnaomics Inc Primary Sclerosing Cholangitis Product and Service
-
14.9 Durect Corporation
-
14.9.1 Durect Corporation Company Details
-
14.9.2 Durect Corporation Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Durect Corporation Primary Sclerosing Cholangitis Product and Service
-
14.10 Intercept Pharmaceuticals Inc
-
14.10.1 Intercept Pharmaceuticals Inc Company Details
-
14.10.2 Intercept Pharmaceuticals Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Intercept Pharmaceuticals Inc Primary Sclerosing Cholangitis Product and Service
-
14.11 Gilead Sciences Inc
-
14.11.1 Gilead Sciences Inc Company Details
-
14.11.2 Gilead Sciences Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Gilead Sciences Inc Primary Sclerosing Cholangitis Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Primary Sclerosing Cholangitis
-
Figure Primary Sclerosing Cholangitis Picture
-
Table Global Primary Sclerosing Cholangitis Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Primary Sclerosing Cholangitis Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Primary Sclerosing Cholangitis Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Primary Sclerosing Cholangitis Consumption by Country (2017-2022)
-
Figure United States Primary Sclerosing Cholangitis Consumption and Growth Rate (2017-2022)
-
Table Europe Primary Sclerosing Cholangitis Consumption and Growth Rate (2017-2022)
-
Figure China Primary Sclerosing Cholangitis Consumption and Growth Rate (2017-2022)
-
Figure Japan Primary Sclerosing Cholangitis Consumption and Growth Rate (2017-2022)
-
Figure India Primary Sclerosing Cholangitis Consumption and Growth Rate (2017-2022)
-
Figure South Korea Primary Sclerosing Cholangitis Consumption and Growth Rate (2017-2022)
-
Figure Global Primary Sclerosing Cholangitis Consumption Forecast by Country (2022-2028)
-
Figure United States Primary Sclerosing Cholangitis Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Primary Sclerosing Cholangitis Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Primary Sclerosing Cholangitis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Primary Sclerosing Cholangitis Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Primary Sclerosing Cholangitis Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Primary Sclerosing Cholangitis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Type I Consumption and Growth Rate (2017-2022)
-
Figure Global Type II Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Type I Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Type II Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Primary Sclerosing Cholangitis Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Primary Sclerosing Cholangitis Export by Region (Top 5 Countries) (2017-2028)
-
Table Shire Plc (Foundation Year, Company Profile and etc.)
-
Table Shire Plc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shire Plc Primary Sclerosing Cholangitis Product and Service
-
Table NGM Biopharmaceuticals Inc (Foundation Year, Company Profile and etc.)
-
Table NGM Biopharmaceuticals Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table NGM Biopharmaceuticals Inc Primary Sclerosing Cholangitis Product and Service
-
Table Conatus Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)
-
Table Conatus Pharmaceuticals Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table Conatus Pharmaceuticals Inc Primary Sclerosing Cholangitis Product and Service
-
Table Dr Falk Pharma GmbH (Foundation Year, Company Profile and etc.)
-
Table Dr Falk Pharma GmbH Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dr Falk Pharma GmbH Primary Sclerosing Cholangitis Product and Service
-
Table Shenzhen HighTide Biopharmaceuticals Ltd (Foundation Year, Company Profile and etc.)
-
Table Shenzhen HighTide Biopharmaceuticals Ltd Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shenzhen HighTide Biopharmaceuticals Ltd Primary Sclerosing Cholangitis Product and Service
-
Table Allergan Plc (Foundation Year, Company Profile and etc.)
-
Table Allergan Plc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table Allergan Plc Primary Sclerosing Cholangitis Product and Service
-
Table Acorda Therapeutics Inc (Foundation Year, Company Profile and etc.)
-
Table Acorda Therapeutics Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table Acorda Therapeutics Inc Primary Sclerosing Cholangitis Product and Service
-
Table Sirnaomics Inc (Foundation Year, Company Profile and etc.)
-
Table Sirnaomics Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sirnaomics Inc Primary Sclerosing Cholangitis Product and Service
-
Table Durect Corporation (Foundation Year, Company Profile and etc.)
-
Table Durect Corporation Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table Durect Corporation Primary Sclerosing Cholangitis Product and Service
-
Table Intercept Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)
-
Table Intercept Pharmaceuticals Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intercept Pharmaceuticals Inc Primary Sclerosing Cholangitis Product and Service
-
Table Gilead Sciences Inc (Foundation Year, Company Profile and etc.)
-
Table Gilead Sciences Inc Primary Sclerosing Cholangitis Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gilead Sciences Inc Primary Sclerosing Cholangitis Product and Service
-
